Medical Technology

@xconomy.com 3 years ago

Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More

@xconomy.com 3 years ago

Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

@xconomy.com 3 years ago

Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

@xconomy.com 3 years ago

Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

@xconomy.com 3 years ago

Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More

@xconomy.com 4 years ago

Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

@xconomy.com 4 years ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 4 years ago

Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy

@xconomy.com 4 years ago

Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More

@xconomy.com 4 years ago

Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More

@xconomy.com 4 years ago

ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

@xconomy.com 4 years ago

Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More

@xconomy.com 4 years ago

Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More